Prosecution Insights
Last updated: May 29, 2026
Application No. 18/275,929

GLOBODERA PALLIDA CONTROL AGENT

Non-Final OA §102
Filed
Aug 04, 2023
Priority
Feb 24, 2021 — JP 2021-027228 +1 more
Examiner
COUGHLIN, MATTHEW P
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nippon Soda Co., Ltd.
OA Round
2 (Non-Final)
71%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
83%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
702 granted / 985 resolved
+11.3% vs TC avg
Moderate +12% lift
Without
With
+11.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
35 currently pending
Career history
1038
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
36.1%
-3.9% vs TC avg
§102
17.9%
-22.1% vs TC avg
§112
14.0%
-26.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 985 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 11 and 16-30 are pending in the application. Claim 11 is rejected. Claims 16-30 are withdrawn from further consideration. Election/Restrictions The instant claims are being examined according to MPEP 803.02 which notes: “If the Markush claim is not allowable, the provisional election will be given effect and examination will be limited to the Markush claim and claims to the elected species, with claims drawn to species patentably distinct from the elected species held withdrawn from further consideration.” In this situation, none of Applicant’s claims embrace the elected species and therefore examination has been limited to Markush-type claim 11 with all other claims withdrawn. The search and examination was extended to include the species cited below under 35 USC 102, which is not allowable. Claims 16-30 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species or invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on December 12th, 2025. Response to Amendment / Argument On page 6 of the response filed April 3rd, 2026, Applicant traverses the improper Markush grouping rejection as it might apply to claim 11. Applicant refers to “the same use;” however this is only one prong of the analysis. Regarding the common structure, Applicant asserts “they clearly fulfill the same purpose in view of the disclosure and should be considered an art recognized class because it is well known that each member can be substituted for each other with the expectation that the intended result will occur.” As noted in the rejection, the structural similarity is physical, chemical or art-recognized class. Applicant provides no basis in the art for the cited assertion and appears to be relying on the instant disclosure itself to establish an art-recognized class. The instant disclosure, however, does not establish an “art-recognized class”. For these reasons, the improper Markush grouping rejection is made over claim 11. All other rejections made in the previous Office Action that do not appear below have been overcome by Applicant's amendments to the claims. Therefore, arguments pertaining to these objections and rejections will not be addressed. Improper Markush Grouping The nonstatutory Markush grouping rejection is based on a judicially approved “improper Markush grouping” doctrine. A Markush claim contains an “improper Markush grouping” if: (1) The species of the Markush group do not share a “single structural similarity,” or (2) the species do not share a common use. Members of a Markush group share a “single structural similarity” when they belong to the same recognized physical or chemical class or to the same art-recognized class. Members of a Markush group share a common use when they are disclosed in the specification or known in the art to be functionally equivalent. When an examiner determines that the species of a Markush group do not share a single structural similarity or do not share a common use, then a rejection on the basis that the claim contains an “improper Markush grouping” is appropriate. See the Federal Register, Vol. 76, No. 27, dated February 9, 2011, page 7166. Claim 11 is rejected under improper Markush grouping as the claims contain an improper grouping of alternatively useable species. In the present case, at least (1) applies. It cannot be said that all members of the Markush group have a single structural similarity. The structures embraced by the permutations of -Y-X- encompass varying heterocyclic structures not recognized as belonging to the same physical or chemical class. For example, in the CPC classification system: compounds containing a 5 or 6-membered oxygen containing heterocycle (corresponding to structures where the partial structure -Xa-Ya- is *-O-(C=X1a)-** or where the partial structure -Xb-Yb- is *-O-C(=S)-**) are classified in various locations including C07D 307/33. compounds containing a 5 or 6-membered sulfur containing heterocycle (corresponding to structures where the partial structure -Xa-Ya- is *-S-(C=X1a)-** or where the partial structure -Xb-Yb- is *-S-C(=O)-**) are classified in various locations including C07D 333/32. compounds containing a 5 or 6-membered nitrogen containing heterocycle (corresponding to structures where the partial structure -Xa-Ya- is *-NH-(C=X1a)-** and the structure of formula I-c) are classified in various locations including C07D 207/267; compounds containing a 5-membered nitrogen and sulfur containing heterocycle (corresponding to structures where the partial structure -Xb-Yb- is *-NH-SO2-**) are classified in various locations including C07D 275/02. Therefore, it cannot be said that all members of the Markush group have a single structural similarity with respect to the functional groups present and the claims therefore are considered to contain an “improper Markush grouping”. Each one of the four groups above represents its own proper Markush grouping. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 11 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Johnson et al. Aust. J. Chem., 1971, 24, 1643-1658. Johnson et al. teach the following compound (12) on page 1647: PNG media_image1.png 260 282 media_image1.png Greyscale PNG media_image2.png 62 479 media_image2.png Greyscale . The prior art teaches the corresponding name 5-hydroxy-5-methyl-4-phenylhexanoic acid lactone on page 1657. The compound is embraced by formula (I-a) where Ar is unsubstituted phenyl, each R1 is C1 alkyl, R2 is hydrogen, Za is an unsubstituted dimethylene group and the partial structure -Xa-Ya- is *-O-C(=X1a)-** where X1a is oxygen. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MATTHEW P COUGHLIN whose telephone number is (571)270-1311. The examiner can normally be reached Monday - Friday, 10 am - 6 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MATTHEW P COUGHLIN/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Aug 04, 2023
Application Filed
Jan 16, 2026
Non-Final Rejection mailed — §102
Apr 03, 2026
Response Filed
Apr 22, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12630541
COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1
4y 7m to grant Granted May 19, 2026
Patent 12630500
HEXASUBSTITUTED RADIALENE COMPOUNDS AND APPLICATIONS THEREOF
3y 3m to grant Granted May 19, 2026
Patent 12630538
ANTI-VIRAL COMPOUNDS
2y 10m to grant Granted May 19, 2026
Patent 12630493
ANTI-INFLAMMATORY COMPOUNDS
2y 9m to grant Granted May 19, 2026
Patent 12600706
METHOD FOR MANUFACTURING LOW-VISCOSITY HARDENER
3y 3m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
71%
Grant Probability
83%
With Interview (+11.8%)
2y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 985 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month